ECX — Epigenomics AG Cashflow Statement
0.000.00%
Last trade - 00:00- €0.61m
- -€2.62m
- €0.49m
Annual cashflow statement for Epigenomics AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.7 | -17 | -11.7 | -2.43 | -12 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.943 | 3.25 | 0.689 | -1.12 | -0.043 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.09 | -0.245 | 0.894 | -1.02 | -0.706 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -10.4 | -13.5 | -9.57 | -4.15 | -12 |
| Capital Expenditures | -0.106 | -0.122 | -0.021 | -0.035 | -1.36 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.83 | 0.169 | 0.024 | 0.996 | -0.335 |
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.724 | 0.047 | 0.003 | 0.961 | -1.7 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.3 | 7.12 | 2.98 | 21.6 | -0.359 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.66 | -6.33 | -6.59 | 19.5 | -12.9 |